19 PRIMECAP Management Allogene Therapeutics Trades
PRIMECAP Management acquired 5.72M Allogene Therapeutics shares worth $6.35M. That's 0.00% of their equity portfolio (277th largest holding). The investor owns 2.53% of the outstanding Allogene Therapeutics stock. The first Allogene Therapeutics trade was made in Q4 2020. Since then PRIMECAP Management bought shares twelve more times and sold shares on six occasions. The investor's estimated purchase price is $113M, resulting in a loss of 94%.
Avg closing price
Price range
Increased shares by 16.0% (+787k shares)
Q2 2025
Avg closing price
$1.33
Price range
$0.95
-
$1.70
Increased shares by 0.1% (+4.5k shares)
Q1 2025
Avg closing price
$1.89
Price range
$1.40
-
$2.84
Sold 13.1% shares (-741k shares)
Q4 2024
Avg closing price
$2.46
Price range
$1.86
-
$3.22
Sold 0.0% shares (-1.97k shares)
Q3 2024
Avg closing price
$2.66
Price range
$2.08
-
$3.50
Increased shares by 4.1% (+222k shares)
Q2 2024
Avg closing price
$2.95
Price range
$2.23
-
$4.38
Increased shares by 3.2% (+167k shares)
Q1 2024
Avg closing price
$4.17
Price range
$2.92
-
$5.63
Sold 0.0% shares (-2.5k shares)
Q4 2023
Avg closing price
$2.84
Price range
$2.28
-
$3.50
Sold 6.3% shares (-352k shares)
Q3 2023
Avg closing price
$4.38
Price range
$3.17
-
$5.96
Sold 2.3% shares (-132k shares)
Q2 2023
Avg closing price
$5.41
Price range
$4.53
-
$6.74
Increased shares by 16.7% (+825k shares)
Q1 2023
Avg closing price
$6.41
Price range
$4.92
-
$8.21
Increased shares by 1.0% (+51.1k shares)
Q4 2022
Avg closing price
$9.26
Price range
$5.62
-
$11.11
Increased shares by 0.2% (+9.9k shares)
Q3 2022
Avg closing price
$13.59
Price range
$10.32
-
$17.28
Sold 0.5% shares (-23.3k shares)
Q2 2022
Avg closing price
$8.88
Price range
$6.78
-
$12.28
Increased shares by 5.2% (+244k shares)
Q1 2022
Avg closing price
$10.42
Price range
$7.65
-
$15.29
Increased shares by 29.3% (+1.06M shares)
Q4 2021
Avg closing price
$17.64
Price range
$13.13
-
$24.52
Increased shares by 0.8% (+27.3k shares)
Q3 2021
Avg closing price
$23.74
Price range
$21.01
-
$27.64
Increased shares by 174.0% (+2.27M shares)
Q2 2021
Avg closing price
$28.52
Price range
$23.49
-
$35.80
Increased shares by 5.4% (+67k shares)
Q1 2021
Avg closing price
$33.73
Price range
$25.79
-
$39.02
New holding (+1.24M shares)
Q4 2020
Avg closing price
$32.59
Price range
$25.24
-
$43.45
News about Allogene Therapeutics Inc and PRIMECAP Management
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.